Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012–2016 Experience

Autor: Mark Higgins, Nataliya Volkova, Kristin Moy, Bruce C. Marshall, Diana Bilton

Publikováno v: Pulmonary Therapy, Vol 6, Iss 1, Pp 141-149 (2020)

Plain Language Summary We performed a study to better understand the long-term impact of treatment with a drug called ivacaftor for patients with cystic fibrosis (CF). Our study used data from CF patient registries in the United Kingdom and the Unite

Externí odkaz: https://doaj.org/article/4ae508c16f82478fa03fcd3afddc6596

Trans-Atlantic collaboration: applying lessons learned from the US CF Foundation quality improvement initiative

Autor: Kathryn A. Sabadosa, Marjorie M. Godfrey, Bruce C. Marshall

Publikováno v: Orphanet Journal of Rare Diseases, Vol 13, Iss S1, Pp 5-11 (2018)

Abstract Background Between 2002 and 2006 France launched a national cystic fibrois (CF) newborn screening program; organized a network of specialized CF care centers; and issued CF diagnostic and treatment standards. To continue to build on this suc

Externí odkaz: https://doaj.org/article/7aaf598120ab41dfb6dd7566dd938dc1

A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment

Autor: Christopher H. Goss, Sonya L. Heltshe, Natalie E. West, Michelle Skalland, Don B. Sanders, Raksha Jain, Tara L. Barto, Barbra Fogarty, Bruce C. Marshall, Donald R. VanDevanter, Patrick A. Flume, Gregory Omlor, Brenda Bourne, Dion Roberts, Vicki Roberts, Samya Nasr, Dawn Kruse, Rachel Linnemann, Tsion Hailemichael, Caralee Forseen, Heidi Stapp, Natalie West, S. Patel, A. Claudio, Jerimiah Lysinger, Amy Harmala, George Solomon, Latona Kersh, Karen Miller, Dixie Durham, Ahmet Uluer, Robert Fowler, Carla Frederick, Nadine Caci, Charlotte Teneback, Julie Sweet, Michael Parkins, Clare Smith, Jennifer Goralski, Kelsey Haywood, Patrick Flume, Caroline Brailsford, Dana Albon, Christie Aderholt, Kimberly McBennett, Cindy Schaefer, Alpa Patel, April Hunt, Lauren Schumacher, Hari Polenakovik, Linda Clark, Jerry Nick, Katie Poch, Dana Kissner, James Cahill, Jorge Lascano, Erin Silverman, John McArdle, Alison Champagne, Robert Vender, Lisa Allwein, Lance Cohen, Norma (Jean) Barton, Tara Barto, Ami Patel, Cynthia Brown, Nia Vorhees, Michael Crosser, Lawrence Scott, Alix Ashare, Barbara Rodgers, Robert Zanni, Lisa Koval, Andrew Braun, Sophia Chiron Stevens, Maria Tupayachi Ortiz, Patricia Graham, Julie Biller, Erin Hubertz, Kathryn Moffett, Tammy Clark, Rebecca Griffith, Nancy Martinez, Sabiha Hussain, Fei Chen, Marie Egan, Catalina Guzman, Janice Wang, Aileen Espinal, Patricia Walker, Anne Kukral, Emily DiMango, Sarah Fracasso Francis, Carlos Milla, Colleen Dunn, Subramanyam Chittivelu, Ashley Scott, Daniel Dorgan, Sharon Ng, Joseph Pilewski, Rose Lanzo, Nauman Chaudary, Ryan Hayden, Steven Scofield, Barb Johnson, Brian Morrissey, Brandt Robinson, Douglas Conrad, Jenna Mielke, Moira Aitken, Chami Sanlors, Ravi Nayak, Freda Branch, Daniel Rosenbluth, Molly Siegel, Anil Ghimire, Mary Forell, Cori Daines, Monica Varela, Leslie Couch, Rebekah Hibbard, Allen Dozor, Armando Ramirez, Victor Ortega, Kathryn Kennedy, David Fish, Karen Longtine

Publikováno v: American Journal of Respiratory and Critical Care Medicine
Am J Respir Crit Care Med

RATIONALE: People with cystic fibrosis (CF) experience acute worsening of respiratory symptoms and lung function known as pulmonary exacerbations. Treatment with intravenous antimicrobials is common; however, there is scant evidence to support a stan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2ceac2492f4c8685f1f6ba01a1ede0c
https://doi.org/10.1164/rccm.202102-0461oc

Survival and Lung Transplant Outcomes for Individuals With Advanced Cystic Fibrosis Lung Disease Living in the United States and Canada

Autor: Aliza K. Fink, Albert Faro, Joshua S. Ostrenga, Sanja Stanojevic, Alexander Elbert, Anne L. Stephenson, Bradley S. Quon, Christopher H. Goss, Kathleen J. Ramos, Xiayi Ma, Bruce C. Marshall, Jenna Sykes, Kristofer Petren

Publikováno v: Chest. 160:843-853

Background Understanding how health outcomes differ for patients with advanced cystic fibrosis (CF) lung disease living in the United States compared with Canada has health policy implications. Research Question What are rates of lung transplant (LTx

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b7d36090d3b099bf9fa3be777af09a83
https://doi.org/10.1016/j.chest.2021.04.010

Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012–2016 Experience

Autor: Bruce C. Marshall, Mark Higgins, Kristin Moy, Diana Bilton, N. Volkova

Publikováno v: Pulmonary Therapy
Pulmonary Therapy, Vol 6, Iss 1, Pp 141-149 (2020)

Introduction In this long-term, postapproval, observational study, data from the US Cystic Fibrosis Foundation Patient Registry and the UK Cystic Fibrosis Registry were used to evaluate the impact of ivacaftor treatment on cystic fibrosis (CF) by com

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::013bbe5522f0d049a988ca6e4727fb90
https://doi.org/10.1007/s41030-020-00115-8